Isis Highlights Robust Drug Portfolio For Diabetes And Obesity At ADA Conference

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced the presentation of new preclinical data showing that antisense drugs potently reduce levels of sodium dependent glucose transporter type 2 (SGLT2), a key component in controlling glucose re-absorption in the kidney and the target of ISIS 388626. In addition, Isis presented results from eight research programs on novel targets that offer new mechanisms to treat metabolic diseases.

More: continued here

Filed under: Diabetes on June 11th, 2008